Beam Therapeutics’ Base Editing Therapy BEAM-302 Shows Rapid, Sustained AAT Increase in Phase 1/2 for Alpha-1 Antitrypsin Deficiency, Targets Accelerated Approval

September 13, 2026

GlobeNewswire / Beam Therapeutics Press Releases USA

Overview

Beam Therapeutics presented updated Phase 1/2 clinical data for its base editing therapy, BEAM-302, for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society Congress 2026. The data demonstrated rapid and sustained increases in total and functional AAT levels after a single dose. Based on discussions with the FDA, Beam plans to pursue an accelerated approval pathway, using AAT biomarkers as the primary endpoint, significantly advancing the potential for early regulatory approval of gene editing therapies for rare diseases.

In Depth

Key Findings

Beam Therapeutics has presented updated data from its Phase 1/2 clinical trial of BEAM-302, a base editing therapy aimed at treating alpha-1 antitrypsin deficiency (AATD), at the European Respiratory Society Congress 2026. This data revealed a rapid and sustained increase in both total and functional alpha-1 antitrypsin (AAT) levels in plasma following a single administration of BEAM-302. Crucially, based on discussions with the U.S. Food and Drug Administration (FDA), the company intends to pursue an accelerated approval pathway, with AAT biomarkers serving as the primary endpoint.

Technical / Clinical Details

BEAM-302 is an in vivo gene editing therapy that utilizes Beam Therapeutics’ proprietary base editing technology to directly correct specific mutations in the SERPINA1 gene, which is responsible for AATD. AATD is a genetic disorder leading to severe lung and liver damage due to a deficiency in the AAT protein, with current established treatments primarily focusing on symptom management. By precisely correcting the mutated gene within liver cells, BEAM-302 aims to enable the body to produce normal, functional AAT. The Phase 1/2 trial data suggests a significant elevation in AAT levels post-administration, holding promise for slowing disease progression and improving patient clinical outcomes.

Background & Context

Base editing is a precise gene editing technology capable of converting one DNA base into another, which is anticipated to offer a higher safety profile compared to conventional CRISPR/Cas9 systems that involve double-strand breaks. For rare diseases like AATD, an accelerated approval pathway using biomarkers as primary endpoints is critical for bringing innovative therapies to patients sooner. The success of such discussions with the FDA indicates a growing flexibility and understanding from regulatory bodies regarding the approval process for gene editing therapies.

Strategic Significance & Outlook

The potential for BEAM-302 to qualify for an accelerated approval pathway is a significant impetus not only for Beam Therapeutics but also for the broader base editing technology landscape. Should further clinical trial data continue to demonstrate robust efficacy and a favorable safety profile, BEAM-302 could become the first foundational cure for AATD patients. This advancement also paves the way for the development of base editing therapies for other genetic disorders, accelerating technological innovation in the regenerative medicine sector.

Source: https://www.globenewswire.com/news-release/2026/09/08/3357432/0/en/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.